vs
CHIMERA INVESTMENT CORP（CIM）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是CHIMERA INVESTMENT CORP的1.9倍（$127.1M vs $66.2M），再鼎医药同比增速更快（17.1% vs 0.5%），过去两年再鼎医药的营收复合增速更高（20.8% vs 0.8%）
Chimera Investment Corp是一家总部位于美国的房地产投资信托，主要投资住宅抵押贷款支持证券、住宅及商业抵押贷款和其他房地产相关金融资产，聚焦为股东创造经风险调整的可持续回报，通过投资组合运营派发定期股息。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CIM vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.9倍
$66.2M
营收增速更快
ZLAB
高出16.6%
0.5%
两年增速更快
ZLAB
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.2M | $127.1M |
| 净利润 | $28.3M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 42.6% | -54.6% |
| 净利率 | 42.8% | — |
| 营收同比 | 0.5% | 17.1% |
| 净利润同比 | 119.3% | — |
| 每股收益（稀释后） | $0.05 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CIMZLAB
| Q4 25 | $66.2M | $127.1M | ||
| Q3 25 | $65.0M | $115.4M | ||
| Q2 25 | $66.0M | $109.1M | ||
| Q1 25 | $69.2M | $105.7M | ||
| Q4 24 | $65.8M | $108.5M | ||
| Q3 24 | $66.5M | $101.8M | ||
| Q2 24 | $67.3M | $100.1M | ||
| Q1 24 | $65.1M | $87.1M |
净利润CIMZLAB
| Q4 25 | $28.3M | — | ||
| Q3 25 | $-580.0K | $-36.0M | ||
| Q2 25 | $35.5M | $-40.7M | ||
| Q1 25 | $167.3M | $-48.4M | ||
| Q4 24 | $-146.5M | — | ||
| Q3 24 | $136.5M | $-41.7M | ||
| Q2 24 | $56.7M | $-80.3M | ||
| Q1 24 | $129.5M | $-53.5M |
毛利率CIMZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CIMZLAB
| Q4 25 | 42.6% | -54.6% | ||
| Q3 25 | -0.5% | -42.3% | ||
| Q2 25 | 54.3% | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | -222.6% | -62.6% | ||
| Q3 24 | — | -66.6% | ||
| Q2 24 | 84.2% | -76.0% | ||
| Q1 24 | — | -80.7% |
净利率CIMZLAB
| Q4 25 | 42.8% | — | ||
| Q3 25 | -0.9% | -31.2% | ||
| Q2 25 | 53.7% | -37.3% | ||
| Q1 25 | 241.7% | -45.8% | ||
| Q4 24 | -222.6% | — | ||
| Q3 24 | 205.4% | -40.9% | ||
| Q2 24 | 84.2% | -80.2% | ||
| Q1 24 | 198.8% | -61.4% |
每股收益（稀释后）CIMZLAB
| Q4 25 | $0.05 | $-0.05 | ||
| Q3 25 | $-0.27 | $-0.03 | ||
| Q2 25 | $0.17 | $-0.04 | ||
| Q1 25 | $1.77 | $-0.04 | ||
| Q4 24 | $-2.06 | $-0.09 | ||
| Q3 24 | $1.39 | $-0.04 | ||
| Q2 24 | $0.41 | $-0.08 | ||
| Q1 24 | $1.36 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $278.6M | $689.6M |
| 总债务越低越好 | $251.5M | — |
| 股东权益账面价值 | $2.6B | $715.5M |
| 总资产 | $15.8B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.10× | — |
8季度趋势，按日历期对齐
现金及短期投资CIMZLAB
| Q4 25 | $278.6M | $689.6M | ||
| Q3 25 | $491.5M | $717.2M | ||
| Q2 25 | $250.2M | $732.2M | ||
| Q1 25 | $253.3M | $757.3M | ||
| Q4 24 | $84.0M | $779.7M | ||
| Q3 24 | $97.3M | $616.1M | ||
| Q2 24 | $162.3M | $630.0M | ||
| Q1 24 | $169.0M | $650.8M |
总债务CIMZLAB
| Q4 25 | $251.5M | — | ||
| Q3 25 | $251.0M | — | ||
| Q2 25 | $135.2M | — | ||
| Q1 25 | $134.9M | — | ||
| Q4 24 | $134.6M | — | ||
| Q3 24 | $134.4M | — | ||
| Q2 24 | $62.4M | — | ||
| Q1 24 | — | — |
股东权益CIMZLAB
| Q4 25 | $2.6B | $715.5M | ||
| Q3 25 | $2.6B | $759.9M | ||
| Q2 25 | $2.6B | $791.7M | ||
| Q1 25 | $2.6B | $810.8M | ||
| Q4 24 | $2.5B | $840.9M | ||
| Q3 24 | $2.7B | $667.7M | ||
| Q2 24 | $2.6B | $704.2M | ||
| Q1 24 | $2.6B | $762.2M |
总资产CIMZLAB
| Q4 25 | $15.8B | $1.2B | ||
| Q3 25 | $15.1B | $1.2B | ||
| Q2 25 | $14.9B | $1.2B | ||
| Q1 25 | $13.2B | $1.2B | ||
| Q4 24 | $13.1B | $1.2B | ||
| Q3 24 | $13.7B | $985.3M | ||
| Q2 24 | $13.1B | $987.4M | ||
| Q1 24 | $12.5B | $988.4M |
负债/权益比CIMZLAB
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.10× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-248.9M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | -8.78× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CIMZLAB
| Q4 25 | $-248.9M | $-26.0M | ||
| Q3 25 | $-137.5M | $-32.0M | ||
| Q2 25 | $-7.4M | $-31.0M | ||
| Q1 25 | $48.8M | $-61.7M | ||
| Q4 24 | $205.7M | $-55.8M | ||
| Q3 24 | $41.4M | $-26.8M | ||
| Q2 24 | $69.0M | $-42.2M | ||
| Q1 24 | $57.3M | $-90.1M |
自由现金流CIMZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率CIMZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度CIMZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率CIMZLAB
| Q4 25 | -8.78× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.21× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 0.44× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CIM
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
